Monkeypox Vaccine: US FDA Eyes Dose-Sparing Strategy For Jynneos

 
• By Sue Sutter

Switching method of administration from subcutaneous to intradermal would increase by five-fold the number of doses of Bavarian Nordic’s vaccine available to combat the outbreak; an EUA declaration would be needed to make this change, FDA commissioner Robert Califf said.

Intradermal administration
US FDA is weighing a shift to intradermal administration as a way of stretching the Jynneos vaccine supply. • Source: Shutterstock

More from Vaccines

More from Pink Sheet